{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T01:12:18Z","timestamp":1779325938402,"version":"3.51.4"},"reference-count":231,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Associazione Italiana Ricerca sul Cancro (AIRC)","award":["15738\/2014"],"award-info":[{"award-number":["15738\/2014"]}]},{"name":"Associazione Italiana Ricerca sul Cancro (AIRC)","award":["232\/2016"],"award-info":[{"award-number":["232\/2016"]}]},{"name":"Department of Excellence","award":["15738\/2014"],"award-info":[{"award-number":["15738\/2014"]}]},{"name":"Department of Excellence","award":["232\/2016"],"award-info":[{"award-number":["232\/2016"]}]},{"name":"Department of Pharmacy, and the Health and Nutritional Sciences, University of Calabria","award":["15738\/2014"],"award-info":[{"award-number":["15738\/2014"]}]},{"name":"Department of Pharmacy, and the Health and Nutritional Sciences, University of Calabria","award":["232\/2016"],"award-info":[{"award-number":["232\/2016"]}]},{"name":"POR Calabria FESR-FSE 2014\/2020-Axis 12","award":["15738\/2014"],"award-info":[{"award-number":["15738\/2014"]}]},{"name":"POR Calabria FESR-FSE 2014\/2020-Axis 12","award":["232\/2016"],"award-info":[{"award-number":["232\/2016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer is a major health burden worldwide. Although the plethora of molecular targets identified in the last decades and the deriving developed treatments, which significantly improved patients\u2019 outcome, the occurrence of resistance to therapies remains the major cause of relapse and mortality. Thus, efforts in identifying new markers to be exploited as molecular targets in cancer therapy are needed. This review will first give a glance on the diagnostic and therapeutic significance of histone deacetylase (HDAC) and voltage gated ion channels (VGICs) in cancer. Nevertheless, HDAC and VGICs have also been reported as molecular targets through which antiepileptic drugs (AEDs) seem to exert their anticancer activity. This should be claimed as a great advantage. Indeed, due to the slowness of drug approval procedures, the attempt to turn to off-label use of already approved medicines would be highly preferable. Therefore, an updated and accurate overview of both preclinical and clinical data of commonly prescribed AEDs (mainly valproic acid, lamotrigine, carbamazepine, phenytoin and gabapentin) in breast, prostate, brain and other cancers will follow. Finally, a glance at the emerging attempt to administer AEDs by means of opportunely designed drug delivery systems (DDSs), so to limit toxicity and improve bioavailability, is also given.<\/jats:p>","DOI":"10.3390\/cancers14184401","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T20:52:25Z","timestamp":1663015945000},"page":"4401","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["From HDAC to Voltage-Gated Ion Channels: What\u2019s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Michele","family":"Pellegrino","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ricci","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosangela","family":"Ceraldi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Nigro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-0496","authenticated-orcid":false,"given":"Daniela","family":"Bonofiglio","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Lanzino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9407-0805","authenticated-orcid":false,"given":"Catia","family":"Morelli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.2174\/0929867325666171129215610","article-title":"Overview on Anticancer Drug Design and Development","volume":"25","author":"Olgen","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mce.2003.10.032","article-title":"Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7","volume":"213","author":"Olsen","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e37230","DOI":"10.5812\/ircmj.37230","article-title":"Comparison of Anticancer Effects of Carbamazepine and Valproic Acid","volume":"18","author":"Akbarzadeh","year":"2016","journal-title":"Iran. Red Crescent Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/or.2021.7937","article-title":"Combination treatment with VPA and MSCs-TRAIL could increase anti-tumor effects against intracranial glioma","volume":"45","author":"Park","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1002\/jcb.27845","article-title":"Synergistic antitumor activity of oridonin and valproic acid on HL-60 leukemia cells","volume":"120","author":"Li","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.2174\/1381612823666171027130003","article-title":"Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management","volume":"23","author":"Vecht","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Brito, B.E., and Garc\u00eda, M.A. (2021). Concomitant Antihyperalgesic and Antitumor Effects of Gabapentin in a Murine Cancer Pain Model. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189671"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11940-020-0613-y","article-title":"Epilepsy in brain metastasis: An emerging entity","volume":"22","author":"Mo","year":"2020","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3904\/kjim.2018.162","article-title":"Neuropathic cancer pain: Prevalence, pathophysiology, and management","volume":"33","author":"Yoon","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3322\/caac.21453","article-title":"Optimal pain management for patients with cancer in the modern era","volume":"68","author":"Scarborough","year":"2018","journal-title":"Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0074-7742(06)81006-8","article-title":"Mechanisms of action of antiepileptic drugs","volume":"81","author":"White","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nature00978","article-title":"The voltage-gated potassium channels and their relatives","volume":"419","author":"Yellen","year":"2002","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1085\/jgp.201611668","article-title":"Mechanism of sodium channel block by local anesthetics, antiarrhythmics, and anticonvulsants","volume":"149","author":"Tikhonov","year":"2017","journal-title":"J. Gen. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/mol.110.064683","article-title":"Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore","volume":"78","author":"Lipkind","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W., and Delgado-Escueta, A.V. (2012). Voltage-Gated Calcium Channels in Epilepsy. Jasper\u2019s Basic Mechanisms of the Epilepsies, Bethesda.","DOI":"10.1093\/med\/9780199746545.001.0001"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/mol.114.097659","article-title":"Structural Basis for Pharmacology of Voltage-Gated Sodium and Calcium Channels","volume":"88","author":"Catterall","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/WCO.0b013e32833735b5","article-title":"Mechanisms of action of antiepileptic drugs: The search for synergy","volume":"23","author":"Stafstrom","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12935-016-0348-8","article-title":"Altering bioelectricity on inhibition of human breast cancer cells","volume":"16","author":"Berzingi","year":"2016","journal-title":"Cancer Cell Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molmed.2010.01.005","article-title":"Ion channels and the hallmarks of cancer","volume":"16","author":"Prevarskaya","year":"2010","journal-title":"Trends Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/embor.2008.75","article-title":"Ion channels: Functional expression and therapeutic potential in cancer. Colloquium on Ion Channels and Cancer","volume":"9","author":"Fraser","year":"2008","journal-title":"EMBO Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20130092","DOI":"10.1098\/rstb.2013.0092","article-title":"Ion transport and cancer: From initiation to metastasis","volume":"369","author":"Djamgoz","year":"2014","journal-title":"Philos. Trans. R. Soc. London. Ser. B Biol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/092986709787002835","article-title":"Targeting ion channels in cancer: A novel frontier in antineoplastic therapy","volume":"16","author":"Arcangeli","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"C541","DOI":"10.1152\/ajpcell.00102.2011","article-title":"Ion channels and transporters [corrected] in cancer. 2. Ion channels and the control of cancer cell migration","volume":"301","author":"Cuddapah","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Serrano-Novillo, C., Capera, J., Colomer-Molera, M., Condom, E., Ferreres, J.C., and Felipe, A. (2019). Implication of Voltage-Gated Potassium Channels in Neoplastic Cell Proliferation. Cancers, 11.","DOI":"10.3390\/cancers11030287"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fonc.2019.00124","article-title":"The Emerging Role of Voltage-Gated Sodium Channels in Tumor Biology","volume":"9","author":"Mao","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Djamgoz, M.B.A., Fraser, S.P., and Brackenbury, W.J. (2019). In Vivo Evidence for Voltage-Gated Sodium Channel Expression in Carcinomas and Potentiation of Metastasis. Cancers, 11.","DOI":"10.3390\/cancers11111675"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1387\/ijdb.150171wb","article-title":"Dual roles of voltage-gated sodium channels in development and cancer","volume":"59","author":"Patel","year":"2015","journal-title":"Int. J. Dev. Biol."},{"key":"ref_29","first-page":"4835","article-title":"NaV1.5 Na(+) channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia","volume":"126","author":"Brisson","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1158\/0008-5472.CAN-10-1169","article-title":"Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion","volume":"70","author":"House","year":"2010","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102270","DOI":"10.1016\/j.isci.2021.102270","article-title":"Pharmacological and nutritional targeting of voltage-gated sodium channels in the treatment of cancers","volume":"24","author":"Pukkanasut","year":"2021","journal-title":"iScience"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wang, C.Y., Lai, M.D., Phan, N.N., Sun, Z., and Lin, Y.C. (2015). Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125766"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/cancers7020813","article-title":"Voltage-gated ion channels in cancer cell proliferation","volume":"7","author":"Rao","year":"2015","journal-title":"Cancers"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/bph.12486","article-title":"Calcium influx pathways in breast cancer: Opportunities for pharmacological intervention","volume":"171","author":"Azimi","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00424-014-1444-z","article-title":"T-type calcium channels blockers as new tools in cancer therapies","volume":"466","author":"Dziegielewska","year":"2014","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.3892\/ol.2017.6457","article-title":"Voltage-gated calcium channels: Novel targets for cancer therapy","volume":"14","author":"Phan","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102610","DOI":"10.1016\/j.ceca.2022.102610","article-title":"T-type channels in cancer cells: Driving in reverse","volume":"105","author":"Alza","year":"2022","journal-title":"Cell Calcium"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-pharmtox-010818-021757","article-title":"Structure and Pharmacology of Voltage-Gated Sodium and Calcium Channels","volume":"60","author":"Catterall","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1146\/annurev-physiol-031620-091043","article-title":"Voltage-Gated Calcium Channels in Nonexcitable Tissues","volume":"83","author":"Pitt","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-014-0277-x","article-title":"The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis","volume":"14","author":"Nelson","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7150\/ijms.13834","article-title":"Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases","volume":"13","author":"Takada","year":"2016","journal-title":"Int. J. Med. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2018.07.057","article-title":"Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer","volume":"835","author":"Heers","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrm3931","article-title":"50 years of protein acetylation: From gene regulation to epigenetics, metabolism and beyond","volume":"16","author":"Verdin","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Elmallah, M.I.Y., and Micheau, O. (2019). Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. Cancers, 11.","DOI":"10.3390\/cancers11060850"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"175216","DOI":"10.1016\/j.ejphar.2022.175216","article-title":"The emerging roles of HDACs and their therapeutic implications in cancer","volume":"931","author":"Hai","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","article-title":"Differential molecular mechanistic behavior of HDACs in cancer progression","volume":"39","author":"Singh","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kaur, S., Rajoria, P., and Chopra, M. (2022). HDAC6: A unique HDAC family member as a cancer target. Cell. Oncol.","DOI":"10.1007\/s13402-022-00704-6"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"948217","DOI":"10.3389\/fchem.2022.948217","article-title":"Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer","volume":"10","author":"Pramanik","year":"2022","journal-title":"Front. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fphar.2015.00273","article-title":"Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast, Colorectal, and Prostate Cancer: A Systematic Review","volume":"6","author":"Martin","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.0013-9580.2004.00104.x","article-title":"The activity of antiepileptic drugs as histone deacetylase inhibitors","volume":"45","author":"Eyal","year":"2004","journal-title":"Epilepsia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"706003","DOI":"10.3389\/fphys.2022.706003","article-title":"Histone Deacetylases as Modulators of the Crosstalk Between Skeletal Muscle and Other Organs","volume":"13","author":"Renzini","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00018-020-03599-4","article-title":"Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance","volume":"78","author":"Bahl","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Korfei, M., and Mahavadi, P. (2022). Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. Cells, 11.","DOI":"10.3390\/cells11101626"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-017-0442-6","article-title":"The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer","volume":"17","author":"Kamarulzaman","year":"2017","journal-title":"Cancer Cell Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"19666","DOI":"10.1038\/srep19666","article-title":"HERG1A potassium channel is the predominant isoform in head and neck squamous cell carcinomas: Evidence for regulation by epigenetic mechanisms","volume":"6","author":"Villaronga","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00228","DOI":"10.1002\/prp2.228","article-title":"Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cells","volume":"4","author":"Ohya","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nm.4284","article-title":"Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel","volume":"23","author":"Vikram","year":"2017","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhang, X., and Patel, D. (2018). Differences in Functional Expression of Connexin43 and Na(V)1.5 by Pan- and Class-Selective Histone Deacetylase Inhibition in Heart. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082288"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"H1139","DOI":"10.1152\/ajpheart.00156.2016","article-title":"Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors","volume":"311","author":"Xu","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.dib.2018.02.058","article-title":"Data for the effect of histone deacetylase inhibitors on voltage- and ligand-gated ion channel gene expression in neurogenic induced-human adipose tissue-derived mesenchymal stem cells","volume":"17","author":"Jang","year":"2018","journal-title":"Data Brief"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103853","DOI":"10.1016\/j.ebiom.2022.103853","article-title":"Depolarization or hyperpolarization: Emerging role of altered bioelectricity in breast cancer metastasis","volume":"76","author":"Yu","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-05-0327","article-title":"Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis","volume":"11","author":"Fraser","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbamem.2003.07.001","article-title":"Involvement of a novel fast inward sodium current in the invasion capacity of a breast cancer cell line","volume":"1616","author":"Roger","year":"2003","journal-title":"Biochim. Et Biophys. Acta"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuropharm.2017.04.014","article-title":"The pharmacology of voltage-gated sodium channel activators","volume":"127","author":"Deuis","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.12688\/f1000research.6789.1","article-title":"Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs","volume":"4","author":"Koltai","year":"2015","journal-title":"F1000Research"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2102-9","article-title":"Therapeutic potential for phenytoin: Targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer","volume":"134","author":"Yang","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"32914","DOI":"10.18632\/oncotarget.5441","article-title":"Nav1.5 regulates breast tumor growth and metastatic dissemination In Vivo","volume":"6","author":"Nelson","year":"2015","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12935-016-0299-0","article-title":"The voltage gated Ca(2+)-channel Cav3.2 and therapeutic responses in breast cancer","volume":"16","author":"Pera","year":"2016","journal-title":"Cancer Cell Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-018-4970-0","article-title":"T-Type voltage gated calcium channels: A target in breast cancer?","volume":"173","author":"Bhargava","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102646","DOI":"10.1016\/j.ebiom.2020.102646","article-title":"Amplification of a calcium channel subunit CACNG4 increases breast cancer metastasis","volume":"52","author":"Kanwar","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.bjp.0705649","article-title":"Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line","volume":"141","author":"Roger","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_74","first-page":"267","article-title":"T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells","volume":"41","author":"Ohkubo","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1742-7843.2012.00880.x","article-title":"Oxidative stress in the in vivo DMBA rat model of breast cancer: Suppression by a voltage-gated sodium channel inhibitor (RS100642)","volume":"111","author":"Batcioglu","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cbf.3626","article-title":"Epigenetic modulators combination with chemotherapy in breast cancer cells","volume":"39","author":"Ari","year":"2021","journal-title":"Cell Biochem. Funct."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.radonc.2015.10.009","article-title":"Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy","volume":"117","author":"Reddy","year":"2015","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Halasa, M., Okon, E., Kukula-Koch, W., and Stepulak, A. (2021). Valproic Acid and Breast Cancer: State of the Art in 2021. Cancers, 13.","DOI":"10.3390\/cancers13143409"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2007.10.006","article-title":"Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells","volume":"259","author":"Fortunati","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2009.09.011","article-title":"Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells","volume":"314","author":"Fortunati","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4238\/2012.January.13.1","article-title":"Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression","volume":"11","author":"Li","year":"2012","journal-title":"Genet. Mol. Res. GMR"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.18632\/oncotarget.6802","article-title":"Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression","volume":"7","author":"Roca","year":"2016","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Luszczki, J.J., Grabarska, A., Gumbarewicz, E., Dmoszynska-Graniczka, M., Polberg, K., and Stepulak, A. (2015). Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines\u2014An Isobolographic Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143013"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2017.12.003","article-title":"Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells","volume":"280","author":"Aztopal","year":"2018","journal-title":"Chem.-Biol. Interact."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/14756366.2016.1210138","article-title":"N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells","volume":"31","author":"Padilla","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/jcb.26512","article-title":"Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors","volume":"119","author":"Tarasenko","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2174\/1871520620666200423073812","article-title":"Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes","volume":"20","author":"Martel","year":"2020","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"646384","DOI":"10.3389\/fimmu.2021.646384","article-title":"Valproic Acid-Like Compounds Enhance and Prolong the Radiotherapy Effect on Breast Cancer by Activating and Maintaining Anti-Tumor Immune Function","volume":"12","author":"Cai","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_90","unstructured":"University of California, and H. Lee Moffitt Cancer Center and Research Institute (2022, September 02). Valproic Acid in Combination with FEC100 for Primary Therapy in Patients with Breast Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01010854."},{"key":"ref_91","unstructured":"National Institute of Cancerolog\u00eda, National Council of Science and Technology, and Psicofarma S.A. de C.V (2022, July 14). Hydralazine and Valproate Added to Chemotherapy for Breast Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00395655."},{"key":"ref_92","unstructured":"M.D. Anderson Cancer Center, and National Cancer Institute (NCI) (2022, July 14). Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01552434."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0165-0173(97)00054-4","article-title":"Sodium channels as molecular targets for antiepileptic drugs","volume":"26","author":"Ragsdale","year":"1998","journal-title":"Brain Res. Brain Res. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/ijo.2015.3239","article-title":"Blockade of voltage-gated sodium channels inhibits invasion of endocrine-resistant breast cancer cells","volume":"48","author":"Mohammed","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00415-017-8391-5","article-title":"Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action","volume":"264","author":"Kopsky","year":"2017","journal-title":"J. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1933719114549853","article-title":"Phenytoin is an estrogen receptor alpha-selective modulator that interacts with helix 12","volume":"22","author":"Fadiel","year":"2015","journal-title":"Reprod. Sci."},{"key":"ref_97","unstructured":"(2022, July 15). Oral SM-88 in Patients with Metastatic HR+\/HER2- Breast Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04720664."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-2999(96)00265-8","article-title":"Lamotrigine inhibits Ca2+ currents in cortical neurons: Functional implications","volume":"307","author":"Stefani","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/exnr.1997.6554","article-title":"Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: Implications for neuroprotective strategies","volume":"147","author":"Stefani","year":"1997","journal-title":"Exp. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000026527","article-title":"Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder","volume":"38","author":"Xie","year":"1998","journal-title":"Neuropsychobiology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"10675","DOI":"10.1074\/jbc.M208356200","article-title":"Binding of the anticonvulsant drug lamotrigine and the neurotoxin batrachotoxin to voltage-gated sodium channels induces conformational changes associated with block and steady-state activation","volume":"278","author":"Cronin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1017\/S1461145712000429","article-title":"Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: Roles of chromatin remodelling and Bcl-2 induction","volume":"16","author":"Leng","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jpsychires.2013.05.028","article-title":"Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL\/6 mice: Brain region specific changes","volume":"47","author":"Ookubo","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/1541-7786.MCR-17-0662","article-title":"FoxO3a Mediates the Inhibitory Effects of the Antiepileptic Drug Lamotrigine on Breast Cancer Growth","volume":"16","author":"Pellegrino","year":"2018","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/25147","article-title":"Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway","volume":"396","author":"Yano","year":"1998","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-5793(03)00055-3","article-title":"Calcium regulates the PI3K-Akt pathway in stretched osteoblasts","volume":"536","author":"Danciu","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kourti, M., Liaropoulou, D., Paschou, M., Giagklisi, I., Paschalidi, M., Petani, E., and Papazafiri, P. (2022). Enhanced Ca(2+) Entry Sustains the Activation of Akt in Glucose Deprived SH-SY5Y Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031386"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/j.bmcl.2012.09.076","article-title":"T-type Ca2+ channel blocker, KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular Ca2+ levels in human lung adenocarcinoma A549 cells","volume":"22","author":"Rim","year":"2012","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bcp.2012.12.017","article-title":"Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells","volume":"85","author":"Valerie","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Pellegrino, M., Rizza, P., Don\u00e0, A., Nigro, A., Ricci, E., Fiorillo, M., Perrotta, I., Lanzino, M., Giordano, C., and Bonofiglio, D. (2019). FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer. Cancers, 11.","DOI":"10.3390\/cancers11121858"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.lfs.2005.01.003","article-title":"Carbamazepine is an inhibitor of histone deacetylases","volume":"76","author":"Beutler","year":"2005","journal-title":"Life Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11010-010-0651-y","article-title":"Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90","volume":"348","author":"Meng","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"ref_113","first-page":"691","article-title":"Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: Drug testing in a 3D model","volume":"88","author":"Teichmann","year":"2014","journal-title":"Arch. Toxicol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"215619","DOI":"10.1016\/j.canlet.2022.215619","article-title":"Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy","volume":"534","author":"Fontana","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Brunello, S., and Salvarese, N. (2022). A Review on the Current State and Future Perspectives of [(99m)Tc]Tc-Housed PSMA-i in Prostate Cancer. Molecules, 27.","DOI":"10.3390\/molecules27092617"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13148-016-0264-8","article-title":"Epigenetic modulators as therapeutic targets in prostate cancer","volume":"8","author":"Henrique","year":"2016","journal-title":"Clin. Epigenet."},{"key":"ref_119","first-page":"29","article-title":"Emerging Roles of Long Non-coding RNAs as Novel Biomarkers in the Diagnosis and Prognosis of Prostate Cancer","volume":"32","author":"Kan","year":"2021","journal-title":"Discov. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s12094-022-02779-x","article-title":"Insights into the therapeutic potential of histone deacetylase inhibitor\/immunotherapy combination regimens in solid tumors","volume":"24","author":"Sedky","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CGC.2003.n.028","article-title":"Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers","volume":"2","author":"Sikes","year":"2003","journal-title":"Clin. Prostate Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/pros.23879","article-title":"T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells","volume":"79","author":"Silvestri","year":"2019","journal-title":"Prostate"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1574892811308010018","article-title":"Calcium channels and prostate cancer","volume":"8","author":"Shapovalov","year":"2013","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2174\/1568009618666180724111604","article-title":"Combination Therapies Using Metformin and\/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions","volume":"19","author":"Tran","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijbiomac.2022.02.094","article-title":"Transforming growth factor-beta (TGF-\u03b2) in prostate cancer: A dual function mediator?","volume":"206","author":"Mirzaei","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_126","first-page":"25","article-title":"Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells","volume":"24","author":"Thelen","year":"2004","journal-title":"Int. J. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/1535-7163.MCT-08-1076","article-title":"Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo","volume":"8","author":"Kortenhorst","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2011.07.015","article-title":"Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells","volume":"311","author":"Chou","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.cad.0000236302.89843.fc","article-title":"Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways","volume":"17","author":"Angelucci","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.2147\/DDDT.S229930","article-title":"Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival","volume":"13","author":"Giordano","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/carcin\/bgt019","article-title":"Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2","volume":"34","author":"Witt","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4161\/auto.22397","article-title":"Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5","volume":"9","author":"Ouyang","year":"2013","journal-title":"Autophagy"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3892\/ol.2016.4880","article-title":"Valproic acid induces autophagy by suppressing the Akt\/mTOR pathway in human prostate cancer cells","volume":"12","author":"Xia","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pros.20587","article-title":"Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo","volume":"67","author":"Shabbeer","year":"2007","journal-title":"Prostate"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"180363","DOI":"10.1155\/2012\/180363","article-title":"Mechanism of growth inhibition of prostate cancer xenografts by valproic acid","volume":"2012","author":"Sidana","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1442-2042.2007.01823.x","article-title":"Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo","volume":"14","author":"Gao","year":"2007","journal-title":"Int. J. Urol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.21873\/anticanres.11077","article-title":"Valproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models","volume":"36","author":"Chelluri","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/abbs\/gmab002","article-title":"Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C\/EBP\u03b1\/SREBP-1 pathway","volume":"53","author":"Pang","year":"2021","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_140","first-page":"1293","article-title":"Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells","volume":"32","author":"Iacopino","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_141","first-page":"614","article-title":"Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression","volume":"66","author":"Zhang","year":"2011","journal-title":"Die Pharm."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1590\/S1415-475738420150028","article-title":"Valproic acid inhibits the invasion of PC3 prostate cancer cells by upregulating the metastasis suppressor protein NDRG1","volume":"38","author":"Lee","year":"2015","journal-title":"Genet. Mol. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11255-013-0609-6","article-title":"Role of SMAD4 in the mechanism of valproic acid\u2019s inhibitory effect on prostate cancer cell invasiveness","volume":"46","author":"Jiang","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-015-2020-4","article-title":"Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4","volume":"142","author":"Lan","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"172551","DOI":"10.1016\/j.ejphar.2019.172551","article-title":"Up-regulation of TIF1\u03b3 by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-\u03b2\/Smad signaling pathway","volume":"860","author":"Qi","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1533033821990064","DOI":"10.1177\/1533033821990064","article-title":"Identification of HCG18 and MCM3AP-AS1 That Associate with Bone Metastasis, Poor Prognosis and Increased Abundance of M2 Macrophage Infiltration in Prostate Cancer","volume":"20","author":"Chen","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/dmd.107.014662","article-title":"Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line","volume":"35","author":"Valentini","year":"2007","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/pros.20708","article-title":"Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma","volume":"68","author":"Angelucci","year":"2008","journal-title":"Prostate"},{"key":"ref_149","first-page":"607480","article-title":"Does valproic acid induce neuroendocrine differentiation in prostate cancer?","volume":"2011","author":"Sidana","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.lfs.2010.12.017","article-title":"Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001","volume":"88","author":"Wedel","year":"2011","journal-title":"Life Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-011-9386-8","article-title":"Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells","volume":"28","author":"Wedel","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3892\/ijmm.2012.1221","article-title":"Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma","volume":"31","author":"Thelen","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Makarevi\u0107, J., Rutz, J., Juengel, E., Maxeiner, S., Tsaur, I., Chun, F.K., Bereiter-Hahn, J., and Blaheta, R.A. (2019). Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro. Cancers, 11.","DOI":"10.3390\/cancers11040566"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Makarevi\u0107, J., Rutz, J., Juengel, E., Maxeiner, S., Mani, J., Vallo, S., Tsaur, I., Roos, F., Chun, F.K., and Blaheta, R.A. (2018). HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression. Cells, 7.","DOI":"10.3390\/cells7090129"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-17-0074","article-title":"The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer","volume":"16","author":"Tran","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"99","DOI":"10.21873\/invivo.11445","article-title":"The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone","volume":"33","author":"Tran","year":"2019","journal-title":"In Vivo"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.jprot.2011.06.016","article-title":"Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis","volume":"74","author":"Ouyang","year":"2011","journal-title":"J. Proteom."},{"key":"ref_158","first-page":"485","article-title":"Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid","volume":"18","author":"Sargazi","year":"2019","journal-title":"EXCLI J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/pros.22525","article-title":"Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion","volume":"72","author":"Hudak","year":"2012","journal-title":"Prostate"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13046-020-01723-7","article-title":"Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition","volume":"39","author":"Iannelli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Pacheco, M.B., Camilo, V., Lopes, N., and Moreira-Silva, F. (2021). Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070670"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/pros.21288","article-title":"Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer","volume":"71","author":"Wedel","year":"2011","journal-title":"Prostate"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1541-7786.MCR-10-0471","article-title":"Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis","volume":"9","author":"Chen","year":"2011","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jsbmb.2010.03.004","article-title":"A combined pretreatment of 1,25-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells","volume":"121","author":"Gavrilov","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1593\/tlo.08136","article-title":"A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy","volume":"1","author":"Sharma","year":"2008","journal-title":"Transl. Oncol."},{"key":"ref_166","unstructured":"(2022, July 21). Valproic Acid in Treating Patients with Progressive, Non-Metastatic Prostate Cancer, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT00670046."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00280-014-2384-1","article-title":"Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers","volume":"73","author":"Wheler","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/AJP.0000000000000014","article-title":"Beyond neuropathic pain: Gabapentin use in cancer pain and perioperative pain","volume":"30","author":"Yan","year":"2014","journal-title":"Clin. J. Pain"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1188\/14.CJON.S3.59-67","article-title":"Hot flash management: Update of the evidence for patients with cancer","volume":"18","author":"Kaplan","year":"2014","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1188\/20.ONF.374-399","article-title":"ONS Guidelines\u2122 for Cancer Treatment-Related Hot Flashes in Women with Breast Cancer and Men with Prostate Cancer","volume":"47","author":"Kaplan","year":"2020","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"12856","DOI":"10.1523\/JNEUROSCI.2700-10.2010","article-title":"The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2","volume":"30","author":"Dolphin","year":"2010","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1038\/onc.2014.467","article-title":"CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis","volume":"34","author":"Warnier","year":"2015","journal-title":"Oncogene"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bcpt.12484","article-title":"Gabapentin, an Analgesic Used Against Cancer-Associated Neuropathic Pain: Effects on Prostate Cancer Progression in an In Vivo Rat Model","volume":"118","author":"Bugan","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jcp.10312","article-title":"Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility","volume":"195","author":"Fraser","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.canlet.2012.03.036","article-title":"Voltage-gated sodium channel activity promotes prostate cancer metastasis in vivo","volume":"323","author":"Yildirim","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/pros.1095","article-title":"Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines","volume":"48","author":"Diss","year":"2001","journal-title":"Prostate"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.pcan.4500796","article-title":"A potential novel marker for human prostate cancer: Voltage-gated sodium channel expression in vivo","volume":"8","author":"Diss","year":"2005","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_178","first-page":"2045","article-title":"Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells","volume":"21","author":"Abdul","year":"2001","journal-title":"Anticancer Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10637-020-00993-4","article-title":"Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer","volume":"39","author":"Gartrell","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CEJ.0b013e32834a7e6f","article-title":"Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer","volume":"21","author":"Stettner","year":"2012","journal-title":"Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. (ECP)"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ijc.33535","article-title":"Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"149","author":"Salminen","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41416-022-01817-3","article-title":"Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"127","author":"Salminen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jcp.20871","article-title":"Functional expression of voltage-gated sodium channels in primary cultures of human cervical cancer","volume":"210","author":"Diaz","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/ijc.26210","article-title":"Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer","volume":"130","author":"Ortiz","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Altamura, C., and Greco, M.R. (2021). Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment. Cancers, 13.","DOI":"10.3390\/cancers13040668"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Brummelhuis, I.S., Fiascone, S.J., Hasselblatt, K.T., Frendl, G., and Elias, K.M. (2021). Voltage-Gated Sodium Channels as Potential Biomarkers and Therapeutic Targets for Epithelial Ovarian Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215437"},{"key":"ref_187","first-page":"1293","article-title":"Expression of voltage-gated sodium channel alpha subunit in human ovarian cancer","volume":"23","author":"Gao","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1038\/srep11541","article-title":"Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion via Persistent MAPK Signaling","volume":"5","author":"House","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1002\/jcp.27399","article-title":"Colorectal cancer invasiveness in vitro: Predominant contribution of neonatal Nav1.5 under normoxia and hypoxia","volume":"234","author":"Guzel","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12957-019-1715-4","article-title":"Over-expression of Nav1.6 channels is associated with lymph node metastases in colorectal cancer","volume":"17","author":"Lin","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canlet.2020.12.017","article-title":"Voltage-gated sodium channel Na(v)1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer","volume":"500","author":"Sui","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Lastraioli, E., Fraser, S.P., Guzel, R.M., Iorio, J., Bencini, L., and Scarpi, E. (2021). Neonatal Nav1.5 Protein Expression in Human Colorectal Cancer: Immunohistochemical Characterization and Clinical Evaluation. Cancers, 13.","DOI":"10.3390\/cancers13153832"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/ijc.30381","article-title":"Voltage-gated sodium channel Nav 1.7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1","volume":"139","author":"Xia","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.3748\/wjg.v25.i38.5732","article-title":"Role of ion channels in gastrointestinal cancer","volume":"25","author":"Anderson","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.biocel.2006.12.007","article-title":"Voltage-gated sodium channels potentiate the invasive capacities of human non-small-cell lung cancer cell lines","volume":"39","author":"Roger","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_196","first-page":"4939","article-title":"Functional expression of the voltage-gated Na\u207a-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells","volume":"126","author":"Campbell","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/092986712798992093","article-title":"Targeting ion channels in leukemias: A new challenge for treatment","volume":"19","author":"Arcangeli","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","article-title":"Epigenetic therapy for ovarian cancer: Promise and progress","volume":"11","author":"Moufarrij","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2174\/13816128113199990528","article-title":"HDAC as a therapeutic target for treatment of endometrial cancers","volume":"20","author":"Ren","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Bajbouj, K., Al-Ali, A., and Ramakrishnan, R.K. (2021). Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111701"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"582370","DOI":"10.3389\/fcell.2020.582370","article-title":"Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?","volume":"8","author":"Mamdani","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/1570159X13666151030162457","article-title":"Epigenetics in Brain Tumors: HDACs Take Center Stage","volume":"14","author":"Savaskan","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"108114","DOI":"10.1016\/j.intimp.2021.108114","article-title":"The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies","volume":"100","author":"Mehrpouri","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Imai, Y., Hirano, M., Kobayashi, M., Futami, M., and Tojo, A. (2019). HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. Cancers, 11.","DOI":"10.3390\/cancers11040475"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2478\/acph-2020-0021","article-title":"Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges","volume":"70","author":"Lipska","year":"2020","journal-title":"Acta Pharm."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Wu, K.C., Liao, K.S., Yeh, L.R., and Wang, Y.K. (2022). Drug Repurposing: The Mechanisms and Signaling Pathways of Anti-Cancer Effects of Anesthetics. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071589"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.phrs.2020.104786","article-title":"Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours?","volume":"156","author":"Cucchiara","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","article-title":"The effects of antiepileptic drugs on the growth of glioblastoma cell lines","volume":"127","author":"Lee","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"687362","DOI":"10.3389\/fonc.2021.687362","article-title":"Valproic Acid: A Promising Therapeutic Agent in Glioma Treatment","volume":"11","author":"Han","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12935-018-0626-8","article-title":"Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis","volume":"18","author":"Scicchitano","year":"2018","journal-title":"Cancer Cell Int."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Ryu, J.Y., Min, K.L., and Chang, M.J. (2019). Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225599"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.seizure.2019.06.019","article-title":"An overview of anti-epileptic therapy management of patients with malignant tumors of the brain undergoing radiation therapy","volume":"70","author":"Julie","year":"2019","journal-title":"Seizure"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.21873\/anticanres.15828","article-title":"Valproic Acid Enhances Radiosensitization via DNA Double-strand Breaks for Boronophenylalanine-mediated Neutron Capture Therapy in Melanoma Cells","volume":"42","author":"Lai","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_214","first-page":"917","article-title":"Effect of valproic acid on the proliferation and apoptosis of the human melanoma G-361 cell line","volume":"71","author":"Chodurek","year":"2014","journal-title":"Acta Pol. Pharm."},{"key":"ref_215","first-page":"2507","article-title":"In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC\/PRF5 Human Hepatocellular Carcinoma Cell Line","volume":"19","author":"Sanaei","year":"2018","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.3892\/or.2013.2747","article-title":"Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis","volume":"30","author":"Han","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s12029-020-00505-w","article-title":"Reactive Oxygen Species-Mediated Mitochondrial Dysfunction Triggers Sodium Valproate-Induced Cytotoxicity in Human Colorectal Adenocarcinoma Cells","volume":"52","author":"Anirudh","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Mackenzie, G.G., Huang, L., Alston, N., Ouyang, N., Vrankova, K., Mattheolabakis, G., Constantinides, P.P., and Rigas, B. (2013). Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061532"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/carcin\/bgz069","article-title":"Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation","volume":"40","author":"Luo","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/carcin\/bgz170","article-title":"Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: Enhanced efficacy when combined with gemcitabine","volume":"41","author":"Luo","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3892\/ijo.2017.4103","article-title":"Phospho-valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles","volume":"51","author":"Mattheolabakis","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1007\/s11033-014-3330-3","article-title":"Valproic acid inhibits the proliferation of SHSY5Y neuroblastoma cancer cells by downregulating URG4\/URGCP and CCND1 gene expression","volume":"41","author":"Dodurga","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_223","first-page":"1795","article-title":"Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo","volume":"25","author":"Michaelis","year":"2004","journal-title":"Int. J. Oncol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/jcb.24422","article-title":"Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt\/survivin independently of HDAC inhibition","volume":"114","author":"Shah","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Park, H.K., Han, B.R., and Park, W.H. (2020). Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2\/M-Phase Arrest and Apoptotic Cell Death. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072649"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/npr2.12196","article-title":"Neuropharmacology of Antiseizure Drugs","volume":"41","author":"Hakami","year":"2021","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"113890","DOI":"10.1016\/j.ejmech.2021.113890","article-title":"Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction","volume":"226","author":"Pal","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2174\/1874467213666200730113828","article-title":"Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells","volume":"14","year":"2021","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"e2000039","DOI":"10.1002\/mabi.202000039","article-title":"Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery","volume":"20","author":"Lindemann","year":"2020","journal-title":"Macromol. Biosci."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jconrel.2020.10.006","article-title":"Biocompatible sulfated valproic acid-coupled polysaccharide-based nanocarriers with HDAC inhibitory activity","volume":"329","author":"Lindemann","year":"2021","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/acsabm.1c01241","article-title":"Green Light-Activated Single-Component Organic Fluorescence-Based Nano-Drug Delivery System for Dual Uncaging of Anticancer Drugs","volume":"5","author":"Singh","year":"2022","journal-title":"ACS Appl. Bio Mater."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4401\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:28:53Z","timestamp":1760142533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":231,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14184401"],"URL":"https:\/\/doi.org\/10.3390\/cancers14184401","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,10]]}}}